fortovase and Dasatinib Interactions

Interactions between fortovase(saquinavir) and Dasatinib (dasatinib)

saquinavir and dasatinib (Major Drug-Drug)

GENERALLY AVOID: Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of dasatinib, which is primarily metabolized by the isoenzyme. In a drug interaction study of 18 patients with solid tumors, coadministration of dasatinib (20 mg once a day) with the potent inhibitor ketoconazole (200 mg twice a day) increased the dasatinib peak plasma concentration (Cmax) and systemic exposure (AUC) by approximately 4- and 5-fold, respectively, compared to administration without ketoconazole. Data are not available for dasatinib in combination with other CYP450 3A4 inhibitors.

MANAGEMENT: The use of dasatinib in combination with potent CYP450 3A4 inhibitors like protease inhibitors, macrolide antibiotics, azole antifungals, and nefazodone should generally be avoided. Close monitoring for toxicity (e.g., myelosuppression, bleeding complications, fluid retention) and a reduction of dasatinib dosage to a range of 20 to 40 mg daily should be considered if there are no alternatives and concomitant use with these agents is necessary.